Mirimus
Stephen Chang is a seasoned professional in the biotechnology and life sciences sector, currently serving as a Strategic Advisor at Senex and Khepri, as well as at Cell One PARTNERS since January 2023. Stephen is also a Board Member at Mirimus since January 2021 and has held significant roles at Histogen, including Board Member and Chair of the Board of Directors until retirement in March 2021. Previous positions include Senior Vice President of R&D at Stemgent Inc., Chief Scientific Officer at CURES, and CEO and President of Multicell Technologies. Stephen holds a PhD in Biochemical Genetics from UC Irvine and completed undergraduate studies at the University of Michigan.
This person is not in the org chart
This person is not in any offices
Mirimus
Mirimus' mission is to change the paradigm of the current drug discovery process by developing superior preclinical RNA interference (RNAi) animal models that can predict toxicities of potential drug therapies without the actual drug itself.